Suppr超能文献

精准医学时代的哮喘:生物制剂和益生菌。

Asthma in the Precision Medicine Era: Biologics and Probiotics.

机构信息

Graduate Institute of Clinical Medicine, School of Medicine, National Taiwan University, Taipei 100, Taiwan.

Department of Medical Research, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei 100, Taiwan.

出版信息

Int J Mol Sci. 2021 Apr 26;22(9):4528. doi: 10.3390/ijms22094528.

Abstract

Asthma is a major global health issue. Over 300 million people worldwide suffer from this chronic inflammatory airway disease. Typical clinical symptoms of asthma are characterized by a recurrent wheezy cough, chest tightness, and shortness of breath. The main goals of asthma management are to alleviate asthma symptoms, reduce the risk of asthma exacerbations, and minimize long-term medicinal adverse effects. However, currently available type 2 T helper cells (Th2)-directed treatments are often ineffective due to the heterogeneity of the asthma subgroups, which manifests clinically with variable and poor treatment responses. Personalized precision therapy of asthma according to individualized clinical characteristics (phenotype) and laboratory biomarkers (endotype) is the future prospect. This mini review discusses the molecular mechanisms underlying asthma pathogenesis, including the hot sought-after topic of microbiota, add-on therapies and the potential application of probiotics in the management of asthma.

摘要

哮喘是一个全球性的主要健康问题。全世界有超过 3 亿人患有这种慢性炎症性气道疾病。哮喘的典型临床症状表现为反复喘息性咳嗽、胸闷和呼吸急促。哮喘管理的主要目标是缓解哮喘症状、降低哮喘恶化的风险,并最大限度地减少长期药物的不良反应。然而,由于哮喘亚组的异质性,目前可用的 2 型 T 辅助细胞(Th2)靶向治疗往往无效,这种异质性在临床上表现为治疗反应的可变性和不佳。根据个体临床特征(表型)和实验室生物标志物(内型)对哮喘进行个性化精准治疗是未来的前景。这篇微型综述讨论了哮喘发病机制的分子机制,包括热门的微生物组研究课题、附加疗法以及益生菌在哮喘管理中的潜在应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72e/8123613/f9dca4e9035f/ijms-22-04528-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验